Table 2 Respondent demographics according to stopping ADT overuse
For patients who come to your practice and are already on ADT monotherapy for localized prostate cancer, would you recommend stopping ADT? | |||
|---|---|---|---|
Yes/probably yes (n = 61) | No/probably no (n = 23) | p-value | |
Gender (n, % male) | 49, 80% | 22, 96% | 0.01 |
Race (n, %) | 0.63 | ||
White | 47, 77% | 18, 78% | |
Non-White | 9, 15% | 2, 9% | |
Prefer not to disclose | 5, 8% | 3, 13% | |
Years in practice (n, %) | 0.16 | ||
Less than 5 years | 13, 21% | 5, 22% | |
5–10 years | 13, 21% | 3, 13% | |
11–15 years | 12, 20% | 0 | |
More than 15 years | 23, 38% | 15, 65% | |
VA practice (n, %) | 0.04 | ||
Full time | 13, 21% | 3, 13% | |
Part time | 23, 38% | 4, 17% | |
None | 25, 41% | 16, 70% | |
Academic affiliation (n, % yes) | 40, 66% | 13, 57% | 0.61 |
Fellowship training in urologic oncology (n, % yes) | 11, 18% | 4, 17% | 1 |
Do you treat patients with metastatic prostate cancer using ADT (n, % yes) | 51, 84% | 19, 83% | 1 |
Does your practice conduct prostate cancer clinical trials (n, % yes) | 29, 48% | 9, 39% | 0.66 |
How confident are you discussing the risks and benefits of ADT monotherapy for patients with localized prostate cancer? (n, %) | 0.27 | ||
Not at all confident | 1, 2% | 0 | |
A little/somewhat confident | 11, 18% | 7, 30% | |
Quite/extremely confident | 49, 80% | 16, 70% | |
Have you ever stopped prescribing ADT as monotherapy for one of your patients with localized prostate cancer? (n, %) | |||
Yes | 47, 77% | 16, 70% | 0.67 |
I prefer to emphasize the following when communicating with patients about stopping ADT for localized prostate cancer: (n, %; [57 of 61 first column responses]) | 0.62 | ||
Harms of continuing ADT | 21, 37% | 10, 45% | |
Neutral | 11, 19% | 5, 23% | |
Benefits of stopping ADT | 25, 44% | 7, 32% | |